Medipharm Labs Corp. · TSX:LABS
Medipharm Labs — Q1 2026 Earnings Presentation
6 slides from Medipharm Labs's earnings presentation, May 13, 2026
Slide 1: MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA
MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA • Q1 2026 Positive Adjusted EBITDA(1) • Net Revenue of $9M with strong gross margins of 37% • OPEX decreased 28% in Q1 2026 versus Q4 2025 • Company is virtually debt free, with a Q1 ending cash balance of $9.9 mill
Slide 2: Commercial Highlights and Financial Results
MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA Commercial Highlights and Financial Results • Q1 2026 revenue was $9 million with a gross margin of 37%, reflecting disciplined product mix and cost control. • International Medical revenue was $4.6 million, represe
Slide 3: Q1 2026 Financial Results Conference Call / Webcast
MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA balance sheet differentiates MediPharm Labs from many industry peers and provides flexibility to fund both organic and selective inorganic growth opportunities as the industry continues to evolve. Q1 2026 Financial
Slide 4: Non-IFRS Measures
MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA The Company carries out its operations in compliance with all applicable laws in the countries in which it operates. Website: www.medipharmlabs.com Non-IFRS Measures This press release contains references to "Adjust
Slide 5: Adjusted EBITDA Reconciliation
MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA Incremental cost of cannabis 9 7 31 42 inventory acquired in a business combination (1) Fair value adjustments in gross profit 148 (127) (139) (93) Indirect tax reassessments (2) - - - - Miscellaneous (5) 171 138 -
Slide 6: Forward-Looking Statements and Contact
MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA to receive regulatory approvals; and other factors discussed in MediPharm's filings, available on the SEDAR+ website at www.sedarplus.ca. There can be no assurance that such statements will prove to be accurate, as